Fig. 2.
Low-risk cases (Sokal’s relative risk < 0.8). Overall survival (A) and time to progression to accelerated or blastic phase (B). P values are .03 and .02. Notice that 10-year survival is 47% in IFN- arm and 30% in chemotherapy arm.
Low-risk cases (Sokal’s relative risk < 0.8). Overall survival (A) and time to progression to accelerated or blastic phase (B). P values are .03 and .02. Notice that 10-year survival is 47% in IFN- arm and 30% in chemotherapy arm.
